Is Talazoparib launched in China?

As of 2023Talazoparib has not yet been launched in China. According to information from the National Medical Products Administration, this drug is currently in the clinical trial stage and may be approved for marketing in China as time goes by.

Talazopanib has been approved in the United States since 2018 to treat adults with HER2-negative breast cancer if the cancer has spread to other parts of the body or is locally advanced. This drug is a treatment option for people with BRCA gene mutations. These individuals should also have been treated with anthracyclines and/or taxanes if they tolerated them. People with hormone receptor-positive breast cancer should only use talazopanib if they have already received ineffective hormone therapy (unless this treatment is not an option). In June 2023, the U.S. Food and Drug Administration (FDA) approved another indication for talazopanib, the combination of enzalutamide (Xtandi) and talazopanib as the initial treatment of patients with partially metastatic castration-resistant prostate cancer, a type of prostate cancer that has spread from the prostate to other parts of the body and no longer responds to standard hormone-blocking treatments.

The specifications of Talazopanib original drug marketed overseasThe price of 0.25mg*30 pills per box may be more than RMB 10,000, and the price of 1mg*30 pills per box may be more than RMB 40,000 (the price may fluctuate due to the exchange rate), which is relatively expensive. There are also cheaper generics of talazopanib overseas. For example, the price of a box of 1mg*30 pills produced by a Laos pharmaceutical factory may be more than 3,000 yuan (the price may fluctuate due to the exchange rate).